Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.

Marcin DzienisJuan CundomChristian Sebastian FuentesAnna SpreaficoMelanie NordlingerAndrea Viviana PastorErin R AlesiAnterpreet NekiAndrea S FungIane Pinto Figueiredo LimaPeter OppeltGeraldo Felicio da Cunha Junior Barbara A BurtnessFabio Andre FrankeJennifer E TsengAbhishek JoshiJoy McCarthyRamona SwabyYulia SidiBurak GumuscuNiroshini NaickerGilberto de Castro Junior

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

Pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity and a manageable safety profile in first-line R/M HNSCC, suggesting this combination may be an alternative option for this patient population.

Keyphrases

phase iii
phase ii
phase ii study
advanced non small cell lung cancer
open label
clinical trial
small cell lung cancer
squamous cell carcinoma
case report
study protocol
placebo controlled
epidermal growth factor receptor